Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study

No evidence exists as to whether body mass index (BMI) impairs clinical outcomes from ALK inhibitors (ALKi) in patients with ALK-rearranged non-small cell lung cancer (NSCLC). Retrospective data of patients affected by metastatic ALK-rearranged NSCLC treated with ALKi were collected. We divided pati...

Full description

Bibliographic Details
Main Authors: Marco Siringo, Gabriella Gentile, Salvatore Caponnetto, Isabella Sperduti, Daniele Santini, Enrico Cortesi, Alain Jonathan Gelibter
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
ALK
Alectinib
NSCLC
BMI
predictive biomarker
Online Access:https://www.mdpi.com/2072-6694/15/13/3422

Internet

https://www.mdpi.com/2072-6694/15/13/3422

Similar Items